Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study

Background: Pain management for cats with degenerative joint disease (DJD) remains a critical unmet need. Recent work has shown promise for a feline-specific anti-nerve growth factor monoclonal antibody (frunevetmab) to deliver safe and effective pain management. Our objectives were to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruen, Margaret E., Myers, Jamie A. E., Lascelles, B. Duncan X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Veterinary Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195238/
https://www.ncbi.nlm.nih.gov/pubmed/34124212
http://dx.doi.org/10.3389/fvets.2021.610028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195238/
https://www.ncbi.nlm.nih.gov/pubmed/34124212
http://dx.doi.org/10.3389/fvets.2021.610028

Ejemplares similares